AG˹ٷ

STOCK TITAN

[8-K] Stereotaxis, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Corvus Pharmaceuticals (CRVS) Q2-25 10-Q highlights

  • Liquidity: Cash & cash equivalents rose to $14.7 m (Dec-24: $8.7 m) and marketable securities to $59.7 m, giving total liquid resources of $74.4 m. Management expects this to fund operations for at least 12 months.
  • Capital events: All June-30-25-expiring warrants were exercised, adding $54.3 m gross; 6.3 m shares and 4.1 m pre-funded warrants issued. Warrant liability of $28.9 m at Dec-24 fell to zero following a $27.1 m fair-value gain YTD. Share count increased to 74.5 m (Dec-24: 67.9 m). A $100 m ATM program remains unused.
  • Operating performance: Company remains pre-revenue. Q2 operating expenses climbed 73% YoY to $10.3 m as R&D nearly doubled to $7.9 m reflecting advancement of Soquelitinib, Ciforadenant and Mupadolimab. Net loss for the quarter widened to $8.0 m (Q2-24: $4.3 m). For the six-month period, a non-cash warrant revaluation gain drove net income of $7.2 m versus a $10.0 m loss in 1H-24; excluding this gain, core loss from operations was $20.2 m.
  • Cash burn: Operating cash outflow was $14.0 m in 1H-25 (1H-24: $10.6 m); net change in cash was +$5.9 m after financing inflows.
  • Pipeline & risk: Still clinical-stage with no product revenue; significant R&D spending and reliance on external capital expected to continue. Management cites adequate cash but will seek additional funding via equity, debt or partnerships.

Corvus Pharmaceuticals (CRVS) evidenze del 10-Q per il Q2-25

  • ܾ徱à: La liquidità e equivalenti di cassa sono aumentati a 14,7 milioni di dollari (Dic-24: 8,7 milioni) e i titoli negoziabili a 59,7 milioni, per un totale di risorse liquide pari a 74,4 milioni. La direzione prevede che questa somma finanzierà le operazioni per almeno 12 mesi.
  • Eventi di capitale: Tutti i warrant in scadenza il 30 giugno 2025 sono stati esercitati, generando un introito lordo di 54,3 milioni; sono state emesse 6,3 milioni di azioni e 4,1 milioni di warrant pre-finanziati. La passività da warrant, pari a 28,9 milioni a Dic-24, è scesa a zero dopo un guadagno di fair value di 27,1 milioni da inizio anno. Il numero di azioni è salito a 74,5 milioni (Dic-24: 67,9 milioni). Un programma ATM da 100 milioni rimane inutilizzato.
  • Performance operativa: La società è ancora in fase pre-ricavi. Le spese operative del Q2 sono aumentate del 73% su base annua a 10,3 milioni, con R&S quasi raddoppiata a 7,9 milioni, riflettendo i progressi di Soquelitinib, Ciforadenant e Mupadolimab. La perdita netta trimestrale si è ampliata a 8,0 milioni (Q2-24: 4,3 milioni). Nel semestre, una rivalutazione non monetaria dei warrant ha generato un utile netto di 7,2 milioni contro una perdita di 10,0 milioni nel 1H-24; escludendo questo guadagno, la perdita operativa core è stata di 20,2 milioni.
  • Consumo di cassa: Il flusso di cassa operativo è stato negativo per 14,0 milioni nel 1H-25 (1H-24: 10,6 milioni); la variazione netta di cassa è stata +5,9 milioni dopo i flussi di finanziamento.
  • Pipeline e rischi: Ancora in fase clinica senza ricavi da prodotti; si prevede un significativo investimento in R&S e dipendenza continua da capitale esterno. La direzione segnala liquidità adeguata ma cercherà finanziamenti aggiuntivi tramite equity, debito o partnership.

Aspectos destacados del 10-Q del Q2-25 de Corvus Pharmaceuticals (CRVS)

  • Liquidez: El efectivo y equivalentes aumentaron a 14,7 millones de dólares (Dic-24: 8,7 millones) y los valores negociables a 59,7 millones, totalizando recursos líquidos por 74,4 millones. La dirección espera que esto financie las operaciones por al menos 12 meses.
  • Eventos de capital: Se ejercieron todos los warrants que vencían el 30 de junio de 2025, aportando 54,3 millones brutos; se emitieron 6,3 millones de acciones y 4,1 millones de warrants prefinanciados. La obligación por warrants de 28,9 millones en Dic-24 se redujo a cero tras una ganancia de valor razonable de 27,1 millones en lo que va del año. El número de acciones aumentó a 74,5 millones (Dic-24: 67,9 millones). Un programa ATM de 100 millones permanece sin usar.
  • Desempeño operativo: La compañía sigue en fase pre-ingresos. Los gastos operativos del Q2 subieron un 73% interanual a 10,3 millones, con I+D casi duplicándose a 7,9 millones, reflejando avances en Soquelitinib, Ciforadenant y Mupadolimab. La pérdida neta trimestral se amplió a 8,0 millones (Q2-24: 4,3 millones). En el semestre, una revalorización no monetaria de warrants generó un ingreso neto de 7,2 millones frente a una pérdida de 10,0 millones en 1S-24; excluyendo esta ganancia, la pérdida operativa core fue de 20,2 millones.
  • Consumo de efectivo: El flujo operativo fue negativo por 14,0 millones en 1S-25 (1S-24: 10,6 millones); el cambio neto en efectivo fue +5,9 millones tras entradas de financiamiento.
  • Pipeline y riesgos: Aún en etapa clínica sin ingresos por productos; se espera un gasto significativo en I+D y dependencia continua de capital externo. La dirección indica liquidez adecuada pero buscará financiamiento adicional vía acciones, deuda o asociaciones.

Corvus Pharmaceuticals (CRVS) 2025� 2분기 10-Q 주요 내용

  • 유동�: 현금 � 현금� 자산� 1,470� 달러� 증가(2024� 12�: 870� 달러), 시장� 증권은 5,970� 달러� � 유동자산은 7,440� 달러� 달함. 경영진은 � 금액� 최소 12개월� 운영 자금� 지원할 것으� 예상.
  • 자본 이벤�: 2025� 6� 30� 만료 예정� 모든 워런트가 행사되어 � 5,430� 달러� 총수� 발생; 630� 주와 410� 개의 선불 워런� 발행. 2024� 12� 기준 2,890� 달러였� 워런� 부채는 올해 들어 2,710� 달러� 공정가� 이익으로 인해 0으로 감소. 주식 수는 7,450� 주로 증가(2024� 12�: 6,790� �). 1� 달러 규모� ATM 프로그램은 아직 사용되지 않음.
  • 운영 실적: 회사� 여전� 매출 � 단계�. 2분기 운영비는 전년 동기 대� 73% 증가� 1,030� 달러�, 연구개발비가 790� 달러� 거의 � � 증가하며 Soquelitinib, Ciforadenant � Mupadolimab 개발 진전� 반영. 분기 순손실은 800� 달러� 확대(Q2-24: 430� 달러). 상반기에� 비현� 워런� 재평가 이익으로 순이� 720� 달러 기록, 1H-24� 1,000� 달러 손실 대� 개선; 이익� 제외하면 핵심 영업손실은 2,020� 달러.
  • 현금 소진: 2025� 상반� 영업 현금 유출은 1,400� 달러(1H-24: 1,060� 달러); 자금 조달 유입 � 현금 순증가� 590� 달러.
  • 파이프라� � 위험: 여전� 임상 단계이며 제품 매출 없음; 상당� 연구개발 지출과 외부 자본 의존 지� 예상. 경영진은 충분� 현금� 보유하고 있으� 주식, 부� 또는 파트너십� 통한 추가 자금 조달� 모색� 계획.

Points clés du 10-Q du T2-25 de Corvus Pharmaceuticals (CRVS)

  • Liquidité : Les liquidités et équivalents de trésorerie ont augmenté à 14,7 M$ (Déc-24 : 8,7 M$) et les titres négociables à 59,7 M$, portant les ressources liquides totales à 74,4 M$. La direction prévoit que cela financera les opérations pendant au moins 12 mois.
  • Événements de capital : Tous les bons de souscription arrivant à échéance le 30 juin 2025 ont été exercés, générant 54,3 M$ brut ; 6,3 M d’actions et 4,1 M de bons préfinancés ont été émis. La dette liée aux bons, qui s’élevait à 28,9 M$ en déc-24, est tombée à zéro suite à un gain de juste valeur de 27,1 M$ depuis le début de l’année. Le nombre d’actions a augmenté à 74,5 M (déc-24 : 67,9 M). Un programme ATM de 100 M$ reste inutilisé.
  • Performance opérationnelle : La société est toujours en phase pré-revenus. Les dépenses opérationnelles du T2 ont augmenté de 73 % en glissement annuel pour atteindre 10,3 M$, avec la R&D qui a presque doublé à 7,9 M$, reflétant les progrès de Soquelitinib, Ciforadenant et Mupadolimab. La perte nette du trimestre s’est creusée à 8,0 M$ (T2-24 : 4,3 M$). Sur six mois, une réévaluation non monétaire des bons a généré un résultat net de 7,2 M$ contre une perte de 10,0 M$ au 1S-24 ; hors ce gain, la perte opérationnelle de base était de 20,2 M$.
  • Consommation de trésorerie : La sortie de trésorerie opérationnelle a été de 14,0 M$ au 1S-25 (1S-24 : 10,6 M$) ; le changement net de trésorerie a été de +5,9 M$ après les entrées de financement.
  • Pipeline & risques : Toujours en phase clinique sans revenus produits ; des dépenses R&D importantes et une dépendance au capital externe sont attendues. La direction indique une trésorerie adéquate mais cherchera des financements supplémentaires via actions, dette ou partenariats.

Corvus Pharmaceuticals (CRVS) Q2-25 10-Q Highlights

  • ܾ徱ä: Bargeld und Zahlungsmitteläquivalente stiegen auf 14,7 Mio. USD (Dez-24: 8,7 Mio. USD) und marktfähige Wertpapiere auf 59,7 Mio. USD, was eine Gesamtsumme liquider Mittel von 74,4 Mio. USD ergibt. Das Management erwartet, dass diese Mittel die Geschäftstätigkeit für mindestens 12 Monate finanzieren.
  • 辱ٲßԲ󳾱: Alle zum 30. Juni 2025 auslaufenden Warrants wurden ausgeübt, was brutto 54,3 Mio. USD einbrachte; 6,3 Mio. Aktien und 4,1 Mio. vorfinanzierte Warrants wurden ausgegeben. Die Warrants-Verbindlichkeit von 28,9 Mio. USD im Dez-24 sank nach einem Fair-Value-Gewinn von 27,1 Mio. USD im Jahresverlauf auf null. Die Aktienanzahl stieg auf 74,5 Mio. (Dez-24: 67,9 Mio.). Ein 100 Mio. USD ATM-Programm ist ungenutzt.
  • Betriebliche Leistung: Das Unternehmen befindet sich weiterhin in der Vorumsatzphase. Die operativen Aufwendungen im Q2 stiegen um 73 % im Jahresvergleich auf 10,3 Mio. USD, wobei die F&E-Ausgaben mit 7,9 Mio. USD fast verdoppelt wurden, was den Fortschritt bei Soquelitinib, Ciforadenant und Mupadolimab widerspiegelt. Der Nettoverlust im Quartal erhöhte sich auf 8,0 Mio. USD (Q2-24: 4,3 Mio. USD). Im Halbjahr führte eine nicht zahlungswirksame Neubewertung der Warrants zu einem Nettoeinkommen von 7,2 Mio. USD gegenüber einem Verlust von 10,0 Mio. USD im 1H-24; ohne diesen Gewinn betrug der Kernverlust aus dem operativen Geschäft 20,2 Mio. USD.
  • Cash-Burn: Der operative Cashflow betrug im 1H-25 -14,0 Mio. USD (1H-24: -10,6 Mio. USD); der Netto-Cash-Bestand erhöhte sich um 5,9 Mio. USD nach Finanzierungseinnahmen.
  • Pipeline & Risiko: Noch in der klinischen Phase ohne Produktumsatz; erhebliche F&E-Ausgaben und Abhängigkeit von externem Kapital werden voraussichtlich anhalten. Das Management sieht ausreichende Liquidität, wird aber zusätzliche Mittel über Eigenkapital, Fremdkapital oder Partnerschaften suchen.
Positive
  • $54.3 m cash inflow from warrant exercises eliminates volatile warrant liability and strengthens liquidity.
  • Total cash & securities increased to $74.4 m, extending runway to at least mid-2026 per management.
  • Open $100 m ATM facility provides flexible, low-cost future financing.
Negative
  • Quarterly net loss widened to $8.0 m on 73% higher operating expenses.
  • Company remains pre-revenue; continued dependence on external capital likely beyond current runway.
  • Dilution: share count up 10% YoY to 74.5 m with further issuances possible via ATM or options.

Insights

TL;DR: Cash runway extended ~12 mths and warrant overhang removed; core burn accelerating, pipeline still pre-revenue—overall neutral to mildly positive.

The warrant exercise is a twofold benefit: $54 m of nondilutive (pre-priced) cash and elimination of a volatile liability, simplifying the cap-table and P&L. Liquid assets of $74 m cover roughly 18�24 months at the current $20 m semi-annual burn, giving management strategic flexibility while Phase 2 work proceeds. However, quarterly R&D spend almost doubled, signalling forthcoming cash needs beyond 2026 unless partnered. Absence of revenue or late-stage assets keeps fundamental risk high. Near-term catalysts will be clinical read-outs; until then, valuation will hinge on cash balance and macro biotech sentiment.

TL;DR: Balance-sheet repair via warrant conversion is constructive; dilution acceptable; cost trend warrants caution.

CRVS executed its capital plan efficiently: warrant holders converted before expiry, injecting capital at $3.50 while shares trade lower, limiting further discounting. Share count rose 10%, reasonable for the cash received. The untouched $100 m ATM provides an additional buffer. From a going-concern perspective the 12-month liquidity statement is reassuring, yet burn acceleration and lack of debt capacity mean equity remains the likely funding path, posing ongoing dilution risk. Overall impact viewed as not highly material until clinical data shifts risk-reward.

Corvus Pharmaceuticals (CRVS) evidenze del 10-Q per il Q2-25

  • ܾ徱à: La liquidità e equivalenti di cassa sono aumentati a 14,7 milioni di dollari (Dic-24: 8,7 milioni) e i titoli negoziabili a 59,7 milioni, per un totale di risorse liquide pari a 74,4 milioni. La direzione prevede che questa somma finanzierà le operazioni per almeno 12 mesi.
  • Eventi di capitale: Tutti i warrant in scadenza il 30 giugno 2025 sono stati esercitati, generando un introito lordo di 54,3 milioni; sono state emesse 6,3 milioni di azioni e 4,1 milioni di warrant pre-finanziati. La passività da warrant, pari a 28,9 milioni a Dic-24, è scesa a zero dopo un guadagno di fair value di 27,1 milioni da inizio anno. Il numero di azioni è salito a 74,5 milioni (Dic-24: 67,9 milioni). Un programma ATM da 100 milioni rimane inutilizzato.
  • Performance operativa: La società è ancora in fase pre-ricavi. Le spese operative del Q2 sono aumentate del 73% su base annua a 10,3 milioni, con R&S quasi raddoppiata a 7,9 milioni, riflettendo i progressi di Soquelitinib, Ciforadenant e Mupadolimab. La perdita netta trimestrale si è ampliata a 8,0 milioni (Q2-24: 4,3 milioni). Nel semestre, una rivalutazione non monetaria dei warrant ha generato un utile netto di 7,2 milioni contro una perdita di 10,0 milioni nel 1H-24; escludendo questo guadagno, la perdita operativa core è stata di 20,2 milioni.
  • Consumo di cassa: Il flusso di cassa operativo è stato negativo per 14,0 milioni nel 1H-25 (1H-24: 10,6 milioni); la variazione netta di cassa è stata +5,9 milioni dopo i flussi di finanziamento.
  • Pipeline e rischi: Ancora in fase clinica senza ricavi da prodotti; si prevede un significativo investimento in R&S e dipendenza continua da capitale esterno. La direzione segnala liquidità adeguata ma cercherà finanziamenti aggiuntivi tramite equity, debito o partnership.

Aspectos destacados del 10-Q del Q2-25 de Corvus Pharmaceuticals (CRVS)

  • Liquidez: El efectivo y equivalentes aumentaron a 14,7 millones de dólares (Dic-24: 8,7 millones) y los valores negociables a 59,7 millones, totalizando recursos líquidos por 74,4 millones. La dirección espera que esto financie las operaciones por al menos 12 meses.
  • Eventos de capital: Se ejercieron todos los warrants que vencían el 30 de junio de 2025, aportando 54,3 millones brutos; se emitieron 6,3 millones de acciones y 4,1 millones de warrants prefinanciados. La obligación por warrants de 28,9 millones en Dic-24 se redujo a cero tras una ganancia de valor razonable de 27,1 millones en lo que va del año. El número de acciones aumentó a 74,5 millones (Dic-24: 67,9 millones). Un programa ATM de 100 millones permanece sin usar.
  • Desempeño operativo: La compañía sigue en fase pre-ingresos. Los gastos operativos del Q2 subieron un 73% interanual a 10,3 millones, con I+D casi duplicándose a 7,9 millones, reflejando avances en Soquelitinib, Ciforadenant y Mupadolimab. La pérdida neta trimestral se amplió a 8,0 millones (Q2-24: 4,3 millones). En el semestre, una revalorización no monetaria de warrants generó un ingreso neto de 7,2 millones frente a una pérdida de 10,0 millones en 1S-24; excluyendo esta ganancia, la pérdida operativa core fue de 20,2 millones.
  • Consumo de efectivo: El flujo operativo fue negativo por 14,0 millones en 1S-25 (1S-24: 10,6 millones); el cambio neto en efectivo fue +5,9 millones tras entradas de financiamiento.
  • Pipeline y riesgos: Aún en etapa clínica sin ingresos por productos; se espera un gasto significativo en I+D y dependencia continua de capital externo. La dirección indica liquidez adecuada pero buscará financiamiento adicional vía acciones, deuda o asociaciones.

Corvus Pharmaceuticals (CRVS) 2025� 2분기 10-Q 주요 내용

  • 유동�: 현금 � 현금� 자산� 1,470� 달러� 증가(2024� 12�: 870� 달러), 시장� 증권은 5,970� 달러� � 유동자산은 7,440� 달러� 달함. 경영진은 � 금액� 최소 12개월� 운영 자금� 지원할 것으� 예상.
  • 자본 이벤�: 2025� 6� 30� 만료 예정� 모든 워런트가 행사되어 � 5,430� 달러� 총수� 발생; 630� 주와 410� 개의 선불 워런� 발행. 2024� 12� 기준 2,890� 달러였� 워런� 부채는 올해 들어 2,710� 달러� 공정가� 이익으로 인해 0으로 감소. 주식 수는 7,450� 주로 증가(2024� 12�: 6,790� �). 1� 달러 규모� ATM 프로그램은 아직 사용되지 않음.
  • 운영 실적: 회사� 여전� 매출 � 단계�. 2분기 운영비는 전년 동기 대� 73% 증가� 1,030� 달러�, 연구개발비가 790� 달러� 거의 � � 증가하며 Soquelitinib, Ciforadenant � Mupadolimab 개발 진전� 반영. 분기 순손실은 800� 달러� 확대(Q2-24: 430� 달러). 상반기에� 비현� 워런� 재평가 이익으로 순이� 720� 달러 기록, 1H-24� 1,000� 달러 손실 대� 개선; 이익� 제외하면 핵심 영업손실은 2,020� 달러.
  • 현금 소진: 2025� 상반� 영업 현금 유출은 1,400� 달러(1H-24: 1,060� 달러); 자금 조달 유입 � 현금 순증가� 590� 달러.
  • 파이프라� � 위험: 여전� 임상 단계이며 제품 매출 없음; 상당� 연구개발 지출과 외부 자본 의존 지� 예상. 경영진은 충분� 현금� 보유하고 있으� 주식, 부� 또는 파트너십� 통한 추가 자금 조달� 모색� 계획.

Points clés du 10-Q du T2-25 de Corvus Pharmaceuticals (CRVS)

  • Liquidité : Les liquidités et équivalents de trésorerie ont augmenté à 14,7 M$ (Déc-24 : 8,7 M$) et les titres négociables à 59,7 M$, portant les ressources liquides totales à 74,4 M$. La direction prévoit que cela financera les opérations pendant au moins 12 mois.
  • Événements de capital : Tous les bons de souscription arrivant à échéance le 30 juin 2025 ont été exercés, générant 54,3 M$ brut ; 6,3 M d’actions et 4,1 M de bons préfinancés ont été émis. La dette liée aux bons, qui s’élevait à 28,9 M$ en déc-24, est tombée à zéro suite à un gain de juste valeur de 27,1 M$ depuis le début de l’année. Le nombre d’actions a augmenté à 74,5 M (déc-24 : 67,9 M). Un programme ATM de 100 M$ reste inutilisé.
  • Performance opérationnelle : La société est toujours en phase pré-revenus. Les dépenses opérationnelles du T2 ont augmenté de 73 % en glissement annuel pour atteindre 10,3 M$, avec la R&D qui a presque doublé à 7,9 M$, reflétant les progrès de Soquelitinib, Ciforadenant et Mupadolimab. La perte nette du trimestre s’est creusée à 8,0 M$ (T2-24 : 4,3 M$). Sur six mois, une réévaluation non monétaire des bons a généré un résultat net de 7,2 M$ contre une perte de 10,0 M$ au 1S-24 ; hors ce gain, la perte opérationnelle de base était de 20,2 M$.
  • Consommation de trésorerie : La sortie de trésorerie opérationnelle a été de 14,0 M$ au 1S-25 (1S-24 : 10,6 M$) ; le changement net de trésorerie a été de +5,9 M$ après les entrées de financement.
  • Pipeline & risques : Toujours en phase clinique sans revenus produits ; des dépenses R&D importantes et une dépendance au capital externe sont attendues. La direction indique une trésorerie adéquate mais cherchera des financements supplémentaires via actions, dette ou partenariats.

Corvus Pharmaceuticals (CRVS) Q2-25 10-Q Highlights

  • ܾ徱ä: Bargeld und Zahlungsmitteläquivalente stiegen auf 14,7 Mio. USD (Dez-24: 8,7 Mio. USD) und marktfähige Wertpapiere auf 59,7 Mio. USD, was eine Gesamtsumme liquider Mittel von 74,4 Mio. USD ergibt. Das Management erwartet, dass diese Mittel die Geschäftstätigkeit für mindestens 12 Monate finanzieren.
  • 辱ٲßԲ󳾱: Alle zum 30. Juni 2025 auslaufenden Warrants wurden ausgeübt, was brutto 54,3 Mio. USD einbrachte; 6,3 Mio. Aktien und 4,1 Mio. vorfinanzierte Warrants wurden ausgegeben. Die Warrants-Verbindlichkeit von 28,9 Mio. USD im Dez-24 sank nach einem Fair-Value-Gewinn von 27,1 Mio. USD im Jahresverlauf auf null. Die Aktienanzahl stieg auf 74,5 Mio. (Dez-24: 67,9 Mio.). Ein 100 Mio. USD ATM-Programm ist ungenutzt.
  • Betriebliche Leistung: Das Unternehmen befindet sich weiterhin in der Vorumsatzphase. Die operativen Aufwendungen im Q2 stiegen um 73 % im Jahresvergleich auf 10,3 Mio. USD, wobei die F&E-Ausgaben mit 7,9 Mio. USD fast verdoppelt wurden, was den Fortschritt bei Soquelitinib, Ciforadenant und Mupadolimab widerspiegelt. Der Nettoverlust im Quartal erhöhte sich auf 8,0 Mio. USD (Q2-24: 4,3 Mio. USD). Im Halbjahr führte eine nicht zahlungswirksame Neubewertung der Warrants zu einem Nettoeinkommen von 7,2 Mio. USD gegenüber einem Verlust von 10,0 Mio. USD im 1H-24; ohne diesen Gewinn betrug der Kernverlust aus dem operativen Geschäft 20,2 Mio. USD.
  • Cash-Burn: Der operative Cashflow betrug im 1H-25 -14,0 Mio. USD (1H-24: -10,6 Mio. USD); der Netto-Cash-Bestand erhöhte sich um 5,9 Mio. USD nach Finanzierungseinnahmen.
  • Pipeline & Risiko: Noch in der klinischen Phase ohne Produktumsatz; erhebliche F&E-Ausgaben und Abhängigkeit von externem Kapital werden voraussichtlich anhalten. Das Management sieht ausreichende Liquidität, wird aber zusätzliche Mittel über Eigenkapital, Fremdkapital oder Partnerschaften suchen.
false 0001289340 0001289340 2025-08-07 2025-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934

 

Date of report (Date of earliest event reported): August 7, 2025

 

STEREOTAXIS, INC.

 

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

(State or Other Jurisdiction of Incorporation)

 

001-36159   94-3120386
(Commission File Number)   (IRS Employer Identification No.)

 

710 North Tucker Boulevard, Suite 110, St. Louis, Missouri   63101
(Address of Principal Executive Offices)   (Zip Code)

 

(314) 678-6100

 

(Registrant’s Telephone Number, Including Area Code)

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act: ☐

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   STXS   NYSE American LLC

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition

 

On August 7, 2025, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2025 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.

 

Forward-Looking Statements and Additional Information

 

Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

 

In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.    
     
99.1   Stereotaxis, Inc. Earnings Press Release dated August 7, 2025.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  STEREOTAXIS, INC.
     
Date: August 7, 2025 By: /s/ Kimberly R. Peery
  Name: Kimberly R. Peery
  Title: Chief Financial Officer

 

 

 

FAQ

How much cash does Corvus Pharmaceuticals (CRVS) have after Q2-25?

CRVS reported $14.7 m in cash and $59.7 m in marketable securities, totaling $74.4 m at 30 Jun 2025.

Why did CRVS report net income for the first half of 2025 despite operating losses?

A $27.1 m non-cash gain from the revaluation of warrant liabilities offset the $20.2 m operating loss, producing $7.2 m net income.

What caused the increase in R&D expenses for CRVS in Q2-25?

R&D rose to $7.9 m (Q2-24: $4.1 m) due to advancing clinical programs for soquelitinib, ciforadenant and mupadolimab.

How did the warrant exercises impact CRVS’s capital structure?

Exercise of 13.1 m common warrants added $54.3 m cash, issued 6.3 m shares & 4.1 m pre-funded warrants, and removed a $28.9 m liability.

Does CRVS have enough funds to operate without raising more capital?

Management believes existing liquidity funds operations for at least 12 months; additional capital will be sought for longer-term plans.

What is the status of CRVS’s at-the-market (ATM) program?

A $100 m ATM agreement with Jefferies was entered Aug 2024; no shares had been sold under it as of 30 Jun 2025.
Stereotaxis Ord

NYSE:STXS

STXS Rankings

STXS Latest News

STXS Latest SEC Filings

STXS Stock Data

202.16M
60.54M
29.61%
44.31%
4.58%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
United States
ST.LOUIS